# 动脉支架市场

> 动脉支架市场研究报告按类型（裸金属支架、药物洗脱支架、生物可吸收支架）、按应用（冠状动脉疾病、外周动脉疾病、神经血管疾病）、按材料（金属支架、高分子支架、组合支架）、按最终用途（医院、门诊手术中心、专科诊所）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.43%
- **2024:** $ 4.8 Billion
- **2025:** $ 5.01 Billion
- **2035:** $ 7.73 Billion
- **Key Players:** Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cordis Corporation (US), Cook Medical (US), Johnson & Johnson (US), Stryker Corporation (US)

**Report ID:** MRFR/HC/36527-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/arterial-stents-market-38501

---

## Market Summary

## **Arterial Stents Market Overview**

As per MRFR analysis, the Arterial Stents Market Size was estimated at 4.79 (USD Billion) in 2024. The Arterial Stents Market Industry is expected to grow from 5.01 (USD Billion) in 2025 to 7.40 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.43% during the forecast period (2025 - 2034).

### **Key Arterial Stents Market Trends Highlighted**

The Arterial Stents Market is driven by an increasing prevalence of cardiovascular diseases, as well as the growing aging population that is susceptible to these conditions. Advancements in technology have led to the development of more effective stents, improving patient outcomes and reducing complications. Additionally, the rising demand for minimally invasive procedures has significantly contributed to the growth of this market.

As healthcare systems aim to provide better treatment options, the focus on developing innovative stent designs and materials continues to enhance the overall efficacy of arterial interventions.  There are ample opportunities to be explored in the area of drug-eluting and bioresorbable stents, which are becoming increasingly popular due to their ability to reduce the rates of restenosis.

**Source: Primary Research, Secondary Research, MRFR Database and Analyst Review**

The introduction of smart technology into-stents which allows monitoring of the patient’s health, is another major opportunity for market growth. Those manufacturers who divert their financial resources toward analysis, as well as prototypes of these advanced products, will most probably be the favorites of this competition. In efforts to ensure that they deliver the best possible outcomes for their patients, healthcare providers will be calling for such innovations in the market. Recent trends point to a growing tendency to tailor stent treatment to the specific stent needs of the patient.

This aspect is in support of the trend toward patient-oriented care that is sought in order to improve satisfaction and treatment outcomes.

There is an increasing trend among medical device companies and research institutes to form partnerships in order to help have joint innovations and fast-track completion of next-generation stents. Also taking center stage is the issue of regulatory approval and guidelines for the application of new technologies in the construction of the stents. It is crucial for the stakeholders who want to remain close to the center of the developments in the Arterial Stents Market to update themselves on these new trends.

## **Arterial Stents Market Drivers**

### Increasing Prevalence of Cardiovascular Diseases

The rising global incidence of cardiovascular diseases (CVDs) is significantly influencing the Arterial Stents Market Industry. Factors such as an increasing aging population, unhealthy lifestyle choices, and a surge in risk factors like obesity, hypertension, and diabetes are contributing to this trend. As CVDs remain one of the leading causes of mortality globally, the demand for effective treatment options, including arterial stents, is on the rise.In turn, this escalating demand drives innovation and expansion in the stent manufacturing sector.

Furthermore, advancements in stent technology, such as drug-eluting stents and bioresorbable stents, are appealing to healthcare providers and patients alike, ultimately promoting the uptake of such devices. With the market projected to see significant growth in the coming years, stakeholders, including manufacturers, healthcare institutions, and investors, are paying close attention to trends within the Arterial Stents Market Industry.

The ongoing awareness and screening programs targeting heart health play a role in the early detection of cardiovascular conditions, further heightening the necessity for interventional procedures that utilize arterial stents. Essentially, the surging prevalence of cardiovascular diseases poses a fundamental driver for the expansion of the Arterial Stents Market, revealing a persistent need for innovative medical solutions designed to enhance patient outcomes and survival rates.

### Technological Advancements in Stent Design

Rapid advancements in technology are enhancing the design and efficacy of arterial stents, making them safer and more effective. The development of drug-eluting stents reduces the risk of restenosis and improves patient outcomes, driving demand in the Arterial Stents Market Industry. These innovations are supported by extensive research, leading to increased investments by manufacturers focused on developing next-generation stents with superior performance.

### Growing Awareness and Preventive Measures

There is a growing public awareness regarding the importance of cardiovascular health, leading to increased screening and preventive measures. This trend is prompting more individuals to seek treatment for underlying cardiovascular conditions, consequently boosting the demand for arterial stents. Healthcare professionals and organizations are also advocating for timely interventions, which further propels the growth of the Arterial Stents Market Industry.

## **Arterial Stents Market Segment Insights:**

### **Arterial Stents Market Type Insights   **

The Arterial Stents Market, through its Type segmentation, showcases a diverse set of offerings, including Bare Metal Stents, Drug-Eluting Stents, and Bioabsorbable Stents, each contributing uniquely to the market landscape. The Bare Metal Stents category was valued at 1.32 USD Billion in 2023 and is projected to rise to 1.8 USD Billion by 2032. This segment is considered important due to its reliability and effectiveness in a variety of clinical scenarios, leading to its stable adoption across healthcare facilities.

Drug-Eluting Stents hold a dominant position within the market, boasting a valuation of 2.72 USD Billion in 2023, anticipated to grow to 4.0 USD Billion by 2032.

This significant valuation reflects their advanced technology that releases medication to help prevent restenosis, which is a major factor driving their popularity among patients and healthcare providers. Meanwhile, the Bioabsorbable Stents segment, although smaller with a valuation of 0.36 USD Billion in 2023, is showing promising growth potential as it offers the innovative possibility of temporary scaffolding that eventually disappears, addressing concerns over long-term foreign body presence in the vasculature.

The trends fueling growth in the Arterial Stents Market include increasing incidences of cardiovascular diseases, advancements in stent technology, and an aging global population, which collectively encourage heightened innovation and development across all Types.However, challenges such as the need for biocompatibility and the efficacy of new materials may affect market dynamics. As the market evolves, opportunities for expanding market penetration and improving patient outcomes present a valuable landscape for industry participants.

The overall Arterial Stents Market data reflects a vibrant industry that continues to adapt and grow, with Drug-Eluting Stents playing a crucial role as the segment that dominates in terms of revenue, catering to the critical need for advanced cardiac care focusing on reducing restenosis rates.This segmentation showcases the importance of each Type in addressing various patient needs and preferences within the broader context of improving cardiovascular health. The discussion around the Arterial Stents Market statistics, especially focusing on these three Types, reveals a well-rounded view of the medical devices that are essential for the effective treatment of vascular diseases.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Arterial Stents Market Application Insights   **

The Arterial Stents Market is projected to be valued at 4.4 USD Billion in 2023 and is likely to expand as the demand for innovative medical solutions increases. The Application segment of this market encompasses critical areas including Coronary Artery Disease, Peripheral Artery Disease, and Neurovascular Disease, each playing a pivotal role in overall market dynamics. Coronary Artery Disease remains a dominant segment, reflecting the growing prevalence of heart-related conditions globally, which emphasizes the need for efficient treatment options.

Peripheral Artery Disease is also significant, being a common circulatory problem that necessitates the adoption of arterial stents to enhance blood flow. The Neurovascular Disease sphere addresses a crucial aspect of healthcare as conditions affecting the brain's blood vessels can lead to severe health consequences, thus highlighting the importance of advancements in stent technology. The interplay of driven market growth factors, such as the aging population and technological advancements coupled with challenges like regulatory hurdles, underscores the evolving landscape of the Arterial Stents Market.

### **Arterial Stents Market Material Insights**

The Arterial Stents Market is poised to reach a valuation of 4.4 Billion USD in 2023, reflecting its significant role in vascular treatments. Within this framework, the Material segment exhibits notable diversity, encompassing various types, including Metallic Stents, Polymer Stents, and Combination Stents. Metallic Stents predominantly dominate the market due to their strength and durability, often seen as the traditional choice for arterial support. However, Polymer Stents have emerged as a critical innovation, featuring biocompatibility and flexibility, catering well to patients with unique needs.

Combination Stents are also gaining traction, providing the advantages of both materials to optimize patient outcomes. Market growth in this segment is bolstered by rising cardiovascular diseases, technological advances in stent design, and an increasing aging population. Nevertheless, challenges such as the risk of complications and stringent regulatory frameworks persist. Each of these materials contributes uniquely to the overall landscape, making the Arterial Stents Market data on these materials crucial for understanding market dynamics and future innovations in the industry.

### **Arterial Stents Market End Use Insights   **

The Arterial Stents Market is expected to showcase significant growth through various end-use segments, notably in Hospitals, Ambulatory Surgical Centers, and Specialized Clinics. In 2023, the overall market is forecasted to be valued at 4.4 billion USD, reflecting a robust demand driven by the increasing prevalence of cardiovascular diseases and advancements in stent technology. Hospitals play a pivotal role in this market due to their comprehensive facilities and access to a wide patient base, often accounting for a majority share in procedures involving arterial stents.

Meanwhile, Ambulatory Surgical Centers are gaining traction, as they offer cost-effective solutions and enhanced patient convenience for less complicated surgical interventions. Specialized Clinics catering to specific cardiovascular issues also contribute significantly to the market by providing targeted care and fostering patient loyalty. The overall segment is influenced by trends such as the rising adoption of minimally invasive techniques, leading to a greater focus on outpatient services and streamlined care processes, thus propelling the market growth.Moreover, all these end-use categories face challenges, including regulatory compliance and the necessity for continuous technological upgrades to meet evolving patient needs.

The Arterial Stents Market statistics clearly highlight these dynamics shaping industry performance and future opportunities.

### **Arterial Stents Market Regional Insights   **

The Arterial Stents Market exhibits a robust landscape, with a total valuation of 4.4 USD Billion in 2023, reflecting strong growth across various regions. North America dominates this market segment with a significant valuation of 1.8 USD Billion in 2023, expected to rise to 2.6 USD Billion by 2032, indicating its majority holding due to advanced healthcare systems and high adoption rates of innovative stent technologies.

Europe follows with a valuation of 1.3 USD Billion in 2023, increasing to 1.9 USD Billion in 2032, driven by rising cardiovascular diseases and effective regulatory frameworks.The Asia-Pacific (APAC) region is emerging as a significant player with a valuation of 1.0 USD Billion this year, set to reach 1.5 USD Billion in 2032, attributed to an expanding patient base and improving healthcare infrastructure.

South America, though smaller, shows steady growth with a valuation of 0.2 USD Billion, expected to rise to 0.3 USD Billion by 2032, while the Middle East and Africa (MEA) represent the smallest market share, valued at 0.1 USD Billion in 2023 and projected to reach 0.2 USD Billion by 2032, underscoring growth potential in these under-penetrated markets.Overall, the Arterial Stents Market segmentation showcases varying growth dynamics driven by innovation, demographic shifts, and regional healthcare advancements.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Arterial Stents Market Key Players and Competitive Insights:**

The Arterial Stents Market is witnessing significant advancements and competitive dynamics as various companies strive to innovate and enhance their product offerings. This market comprises a variety of stents used in treating arterial blockages, which are critical for improving patient outcomes and quality of life. The competitive landscape is characterized by collaborations, mergers, acquisitions, and the development of next-generation stents, including drug-eluting and bioresorbable stents. With an increasing prevalence of cardiovascular diseases and technological advancements in medical devices, additional market drivers are anticipated to shape the landscape, enabling companies to grow their market share while addressing patients' diverse needs.

The presence of established players and emerging entities continues to enrich the competition, compelling manufacturers to prioritize R&D and marketing strategies, further fueling the growth of the Arterial Stents Market.Focusing specifically on Terumo Corporation, the company has established a strong foothold in the Arterial Stents Market, primarily through its commitment to quality and innovation. Terumo's stent offerings are recognized for their advanced design and biocompatibility, catering to the growing demand for effective treatment options for arterial diseases.

The company strategically invests in research and development, which allows it to introduce cutting-edge technologies that address the intricate needs of vascular interventions. Additionally, it has formed robust partnerships with healthcare providers and medical institutions, reinforcing its market presence and enhancing its reputation within the cardiovascular space. Terumo Corporation's strengths also lie in its comprehensive product portfolio and effective distribution strategies, ensuring accessibility of its stent solutions across various regions, thereby solidifying its competitive advantage in the market.

Abbott Laboratories holds a prominent position within the Arterial Stents Market, distinguishing itself through its innovative approaches and extensive experience in the cardiovascular sector. The company’s stent systems are widely recognized for their efficacy and safety, driven by continuous advancements that reflect the latest scientific research and technological breakthroughs.

Abbott's commitment to enhancing patient care is evident through its focus on developing drug-eluting stents that not only provide immediate relief from arterial blockages but also the sustained release of medications to minimize further complications. The company leverages its strong brand recognition and a well-established distribution network to ensure the widespread availability of its products, catering to a global consumer base. Furthermore, Abbott Laboratories prioritizes clinical evidence and patient outcomes, which enhances its credibility and fosters trust among healthcare professionals, thus reinforcing its competitive stance in the arterial stents market.

### **Key Companies in the Arterial Stents Market Include:**

- Terumo Corporation
- Abbott Laboratories
- Merit Medical Systems
- Acandis
- MicroPort Scientific
- Cardinal Health
- Cook Medical
- Braun Melsungen
- Optimed Medizinische Instrumente
- Boston Scientific
- L. Gore and  Associates
- Royal Philips
- **[Mayoclinic](https://www.mayoclinic.org/tests-procedures/coronary-angioplasty/about/pac-20384761)**
- Johnson and  Johnson
- Gore Medical

### Arterial Stents Market Industry Developments

- **Q2 2024: Boston Scientific to acquire Silk Road Medical for $1.2 billion** Boston Scientific announced a definitive agreement to acquire Silk Road Medical, a company specializing in transcarotid artery revascularization and stent systems, for $1.2 billion to expand its vascular intervention portfolio.
- **Q2 2024: FDA approves Medtronic's Onyx Frontier drug-eluting stent for U.S. market** Medtronic received FDA approval for its Onyx Frontier drug-eluting stent, designed for the treatment of coronary artery disease, marking a significant regulatory milestone for the company's interventional cardiology business.
- **Q2 2024: Abbott Receives CE Mark for Navitor Transcatheter Aortic Valve Implantation System** Abbott announced it has received CE Mark approval for its Navitor TAVI system, which includes a new arterial stent design for minimally invasive heart valve replacement procedures in Europe.
- **Q3 2024: Biotronik launches Pulsar-18 T3 peripheral self-expanding stent in the U.S.** Biotronik announced the U.S. commercial launch of its Pulsar-18 T3 peripheral self-expanding stent, designed for the treatment of femoropopliteal arterial disease, expanding its vascular intervention product line.
- **Q3 2024: MicroPort Scientific Corporation receives NMPA approval for Firehawk Liberty drug-eluting stent in China** MicroPort Scientific Corporation announced that its Firehawk Liberty drug-eluting stent has received regulatory approval from the National Medical Products Administration (NMPA) in China for the treatment of coronary artery disease.
- **Q3 2024: Cordis Announces FDA Clearance of SABERX Drug-Coated Balloon and Launch of New Stent Platform** Cordis received FDA clearance for its SABERX drug-coated balloon and simultaneously launched a new peripheral arterial stent platform in the United States, enhancing its endovascular product offerings.
- **Q4 2024: Boston Scientific launches Synergy XD drug-eluting stent in Europe** Boston Scientific announced the European launch of its Synergy XD drug-eluting stent, designed to improve deliverability and clinical outcomes for patients with coronary artery disease.
- **Q4 2024: Terumo receives FDA approval for Ultimaster Tansei drug-eluting stent** Terumo announced it has received FDA approval for its Ultimaster Tansei drug-eluting stent, enabling the company to expand its presence in the U.S. coronary intervention market.
- **Q1 2025: Medtronic launches Resolute Onyx 2.0 mm drug-eluting stent in Japan** Medtronic announced the commercial launch of its Resolute Onyx 2.0 mm drug-eluting stent in Japan, targeting the treatment of small vessel coronary artery disease.
- **Q1 2025: Biosensors International receives CE Mark for BioFreedom Ultra drug-coated stent** Biosensors International announced it has received CE Mark approval for its BioFreedom Ultra drug-coated stent, allowing commercialization in the European Union for patients with coronary artery disease.
- **Q2 2025: Abbott to open new manufacturing facility for vascular devices in Ireland** Abbott announced plans to open a new manufacturing facility in Ireland dedicated to the production of vascular devices, including arterial stents, to meet growing global demand.
- **Q2 2025: Boston Scientific appoints new president for Interventional Cardiology division** Boston Scientific announced the appointment of a new president for its Interventional Cardiology division, responsible for overseeing the company's arterial stents and related product lines.

The current affairs indicate a competitive market environment, with major players actively seeking to capture market share while adapting to evolving healthcare needs. The overall market valuation is witnessing an upward trajectory, driven by the rising prevalence of cardiovascular diseases, which further stimulates demand for advanced stent technologies. This fiscal trend underscores a healthy growth outlook for the Arterial Stents Market as leading firms continue to invest in research and development to enhance treatment options available to healthcare providers.

## **Arterial Stents Market Segmentation Insights**

### **Arterial Stents Market Type Outlook**

- Bare Metal Stents
- Drug-Eluting Stents
- Bioabsorbable Stents

### **Arterial Stents Market Application Outlook**

- Coronary Artery Disease
- [Peripheral Artery Disease](../../../reports/peripheral-artery-disease-market-1540)
- Neurovascular Disease

### **Arterial Stents Market Material Outlook**

- Metallic Stents
- Polymer Stents
- Combination Stents

### **Arterial Stents Market End Use Outlook**

- Hospitals
- Ambulatory Surgical Centers
- Specialized Clinics

### **Arterial Stents Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 医疗支出上升

各地区医疗支出的增加是动脉支架市场的重要驱动因素。随着政府和私营部门向医疗保健分配更多资源，先进医疗技术（包括动脉支架）的可用性得以改善。这一趋势在新兴经济体中尤为明显，随着可支配收入的增加和中产阶级的壮大，医疗服务的支出也在增加。动脉支架市场将从这一趋势中受益，因为越来越多的患者能够获得必要的治疗。此外，预防性护理和心血管疾病早期干预的重视可能会推动支架手术的需求，从而促进市场增长。医疗投资与创新医疗设备采用之间的相关性预计将保持强劲。

### 监管支持和报销政策

动脉支架市场的关键驱动因素是监管支持和有利的报销政策。各国政府和卫生当局越来越认识到心血管健康的重要性，导致制定促进动脉支架使用的指导方针。这些法规通常加快了新支架技术的审批，鼓励行业内的创新。此外，有利的报销政策增强了患者对支架手术的可及性，从而推动市场增长。随着医疗系统的发展，监管框架与技术进步的对齐可能会进一步促进动脉支架市场的发展。监管机构与行业利益相关者之间的持续合作预计将为新支架解决方案的开发和采用创造有利环境。

### 支架设计中的技术创新

支架设计和材料的技术进步正在显著影响动脉支架市场。药物洗脱支架和生物可吸收支架等创新正在提高手术的有效性和安全性。这些进展不仅改善了患者的治疗效果，还降低了并发症的风险，这在心血管疾病的治疗中至关重要。先进成像技术和微创手术的引入进一步推动了市场的发展，使得支架的放置更加精确，患者体验更佳。随着行业的不断发展，智能技术的整合，如传感器和药物输送系统，预计将彻底改变动脉支架市场，可能导致医疗服务提供者的采用率提高。

### 老龄化人口与生活方式变化

老龄化人口和生活方式的变化是推动动脉支架市场的关键因素。随着预期寿命的增加，年龄相关的心血管疾病的患病率上升，迫切需要有效的治疗选择，如动脉支架。此外，生活方式的改变，包括不良饮食习惯和久坐行为，导致心脏病发病率的增加。这一人口结构的变化促使医疗服务提供者寻求先进的解决方案来管理心血管健康。随着医疗系统适应这些人口趋势，动脉支架市场可能会扩大，重点关注满足老年患者需求的创新支架解决方案。老龄化人口与生活方式相关健康问题之间的相互作用预计将持续推动对动脉支架的需求。

### 心血管疾病的发病率不断增加

心血管疾病发病率的上升是动脉支架市场的主要驱动因素。随着人口老龄化和与生活方式相关的健康问题日益普遍，对有效治疗方案的需求不断增加。根据最新数据，心血管疾病占全球死亡率的相当大比例，迫切需要进行如支架植入等干预措施。这一趋势可能会持续下去，因为医疗系统越来越重视心血管健康。动脉支架市场预计将响应这一日益增长的需求而扩展，支架技术的创新将改善患者的治疗效果并推动市场增长。此外，患者对心脏健康的认识不断提高，可能会进一步推动对动脉支架的需求，因为个人寻求预防措施和现有病症的治疗。

## Future Outlook

动脉支架市场预计将在2024年至2035年间以4.43%的年均增长率增长，推动因素包括技术进步、心血管疾病增加和医疗支出上升。

**New opportunities:**

- 开发可生物降解的支架以提高患者的治疗效果。

到2035年，动脉支架市场预计将实现显著增长和创新。

## Segment Insights

### 按类型：药物洗脱支架（最大）与生物可吸收支架（增长最快）

动脉支架市场主要分为三个关键细分市场：裸金属支架、药物洗脱支架（DES）和生物可吸收支架。在这三者中，药物洗脱支架因其在降低再狭窄率和改善临床结果方面的有效性而占据最大的市场份额。虽然裸金属支架因其简单性和成本效益而传统上受到欢迎，但其市场地位正日益受到药物洗脱支架和生物可吸收支架创新的挑战。

动脉支架市场的增长趋势受到技术进步、心血管疾病的发病率增加以及对微创手术选项需求增长的强烈影响。药物洗脱支架继续主导市场，因为其先进的设计最小化了手术后血管狭窄的风险。另一方面，生物可吸收支架作为增长最快的细分市场正在崛起，因其在愈合期间提供临时支持的潜力，同时最终溶解，从而减少与永久植入物相关的长期并发症。

药物洗脱支架（主导）与生物可吸收支架（新兴）

药物洗脱支架（DES）被认为是动脉支架市场的主导选择，以其独特的释放抑制细胞增殖的药物的能力而闻名。这显著降低了再狭窄的几率，使其成为面临动脉再狭窄风险患者的首选。DES广泛应用于各种手术，并得到了大量临床研究的支持，证明了其有效性和安全性。相比之下，生物可吸收支架代表了一个新兴领域，旨在解决永久性支架的局限性。这些创新支架会随着时间的推移逐渐溶解，愈合后不留任何外来材料在动脉中。它们的吸引力在于潜在的并发症减少和长期结果改善，推动了医疗服务提供者的投资和兴趣不断增加。

### 按应用：冠状动脉疾病（最大）与外周动脉疾病（增长最快）

在动脉支架市场中，应用细分主要分为三个关键领域：冠状动脉疾病、外周动脉疾病和神经血管疾病。在这三者中，冠状动脉疾病作为最大的细分市场，占据了相当大的市场份额。该细分市场的主导地位是由于冠状病症的高发病率，迫切需要有效的支架解决方案。同时，外周动脉疾病细分市场正在迅速增长，表明人们对该疾病的认识和检测率不断提高，以及针对外周应用的支架技术的进步。

冠状动脉疾病（显性）与外周动脉疾病（新兴）

冠状动脉疾病（CAD）仍然是动脉支架市场的主要应用，因为其发病率高且临床干预需求显著。用于CAD手术的支架展现出先进的设计，以增强与各种冠状解剖结构的兼容性并改善患者的治疗效果。相比之下，外周动脉疾病（PAD）代表了一个新兴领域，随着医疗服务提供者认识到其日益增长的流行程度及相关并发症，正逐渐受到重视。PAD支架解决方案的创新旨在提供更好的可输送性和耐用性，以满足更广泛的患者人群，从而推动该细分市场的快速增长。

### 按材料分类：金属支架（最大）与聚合物支架（增长最快）

在动脉支架市场中，金属支架占据了最大的市场份额，由于其在临床环境中的成熟应用和可靠性，主导了市场格局。它们因其优越的强度和出色的灵活性而被广泛采用，适用于各种动脉需求。同时，聚合物支架逐渐获得关注，以满足对生物相容材料日益增长的需求。这一转变反映了临床医生对减少再狭窄风险和改善患者结果的替代方案的显著兴趣。

支架类型：金属（主导）与聚合物（新兴）

金属支架以其坚固的设计和长期有效的治疗动脉阻塞的能力而著称，使其成为医疗专业人员的主流选择。它们能够承受显著的机械压力，同时保持结构完整性，使其成为各种患者的可靠解决方案。另一方面，聚合物支架由于材料科学的进步而逐渐成为首选选项，这些进步使其具有更大的灵活性和降低的血栓形成反应。这些创新增强了支架的安全性，吸引了越来越多关注以患者为中心解决方案的市场细分。

### 按最终用途：医院（最大）与门诊手术中心（增长最快）

在动脉支架市场中，医院代表了最大的终端使用细分市场，由于其全面的资源、专业的设备和熟练的医疗专业人员的可用性，医院占据了大部分市场份额。它们提供广泛的服务，使其成为需要动脉干预的患者的首选。相反，门诊手术中心正在快速增长，这得益于对门诊手术的日益偏好、成本效益解决方案和更短的恢复时间，导致向这些设施的显著转变。

医院（主导）与门诊手术中心（新兴）

医院在动脉支架市场中占据主导地位，因其拥有广泛的医疗基础设施、专业的人员和先进的技术。这些设施能够处理复杂的病例，提供多种动脉支架手术，满足广泛的患者人群。相比之下，门诊手术中心作为一种流行的替代选择，主要用于选择性手术。它们专注于门诊护理，促进便利性和降低成本，从而吸引越来越多的患者。这一转变反映了向微创干预和以患者为中心的护理的趋势，使门诊手术中心成为市场中的重要参与者。

## Regional Market Share Analysis

### 北美：创新的市场领导者

北美是动脉支架最大的市场，占全球市场份额的约45%。该地区的增长受到先进医疗基础设施、心血管疾病日益普遍以及对研发的强烈关注的推动。来自FDA等机构的监管支持进一步催化了创新和市场扩展，确保新技术能够迅速被采用。美国是该市场的主要贡献者，主要参与者包括美敦力、波士顿科学和雅培实验室，主导着竞争格局。这些大型公司的存在为创新和竞争创造了良好的环境。此外，日益增长的老年人口和不断上升的医疗支出预计将在未来几年内持续推动动脉支架的需求。

### 欧洲：新兴的监管框架

欧洲是动脉支架第二大市场，约占全球市场份额的30%。该地区的增长受到对心血管健康意识的提高、医疗技术的进步以及支持性监管框架的推动。欧洲药品管理局（EMA）在确保新支架技术符合安全和有效性标准方面发挥着关键作用，这鼓励了创新和市场进入。该地区的主要国家包括德国、法国和英国，这里强大的医疗系统和高患者意识促进了市场增长。主要参与者如巴布劳梅尔松公司和Terumo公司积极参与扩展其产品供应。竞争格局的特点是持续的创新和战略合作伙伴关系，增强了先进支架解决方案的可用性。

### 亚太地区：快速增长的市场潜力

亚太地区的动脉支架市场正在迅速增长，约占全球市场份额的20%。该地区的扩展受到医疗投资增加、生活方式相关疾病日益普遍以及中产阶级人口增长的推动。中国和印度等国处于前沿，政府倡导改善医疗服务的可及性和可负担性，这对市场增长至关重要。中国是该地区最大的市场，地方制造商和国际参与者的贡献显著。竞争格局正在演变，Cordis公司和Cook Medical等公司正在扩大其市场份额。对微创手术的日益关注以及支架设计的技术进步预计将在未来几年推动进一步增长。

### 中东和非洲：未开发的市场机会

中东和非洲地区在动脉支架市场中占据较小的份额，约为5%，但其增长潜力显著。市场受到医疗投资增加、心血管疾病意识提高以及医疗基础设施改善的推动。然而，经济差异和不同的监管环境等挑战可能会在某些地区阻碍市场增长。南非和阿联酋等国在市场中处于领先地位，医疗设施数量不断增加，患者获得先进医疗技术的机会也在上升。主要参与者开始探索该地区的机会，专注于合作伙伴关系和合作，以增强市场渗透。随着越来越多的公司认识到这一新兴市场的潜力，竞争格局正在逐渐演变。

## Competitive Benchmarking

动脉支架市场的特点是动态的竞争格局，受到技术进步、心血管疾病的日益普遍以及日益增长的老龄化人口的推动。主要参与者如美敦力（美国）、波士顿科学（美国）和雅培实验室（美国）处于市场前沿，各自采用不同的策略来增强市场存在感。美敦力（美国）专注于通过开发下一代支架技术进行创新，而波士顿科学（美国）则强调战略合作伙伴关系以扩展其产品组合。雅培实验室（美国）利用其强大的研究能力推出先进的药物洗脱支架，从而增强其竞争地位。这些策略共同促进了一个强大的竞争环境，推动市场内的持续改进和创新。

这些公司采用的关键商业策略包括本地化制造和优化供应链，以提高运营效率。动脉支架市场似乎适度分散，既有成熟的参与者，也有新兴公司。主要参与者的集体影响塑造了市场动态，因为他们不仅在产品质量上竞争，还在服务交付和技术进步上竞争。

2025年8月，美敦力（美国）宣布推出其最新的药物洗脱支架，该支架采用先进的生物可吸收技术，旨在降低再狭窄的风险。这一战略举措具有重要意义，因为它使美敦力（美国）能够通过满足对创新解决方案的日益需求来获取更大的市场份额，从而改善患者的治疗效果。预计这一产品的推出将增强美敦力（美国）在快速发展的市场中的竞争优势。

2025年9月，波士顿科学（美国）与一家领先的数字健康公司达成战略合作伙伴关系，将人工智能驱动的分析集成到其支架监测系统中。这一合作表明了医疗保健行业向数字化的更广泛趋势，表明波士顿科学（美国）希望通过技术提升患者管理和治疗效果。这类举措不仅可能提高运营效率，还可能在一个日益关注数据驱动解决方案的市场中提供竞争优势。

2025年7月，雅培实验室（美国）在欧洲扩大了其制造能力，以满足对其创新支架产品日益增长的需求。这一扩展反映了雅培（美国）对区域增长和供应链优化的承诺，这在保持竞争优势方面至关重要。通过增强生产能力，雅培（美国）可能会提高对市场需求的响应能力，并增强其在竞争对手面前的地位。

截至2025年10月，动脉支架市场的当前竞争趋势越来越多地受到数字化、可持续性和人工智能整合的定义。战略联盟变得越来越普遍，因为公司认识到合作在推动创新和增强产品供应方面的重要性。展望未来，竞争差异化预计将演变，显著转向从基于价格的竞争转向关注创新、技术进步和供应链可靠性。这一转变可能会重新定义市场动态，迫使公司投资于研发，以在竞争激烈的环境中保持领先。

## Recent News & Developments

- **2024年第二季度：波士顿科学以12亿美元收购Silk Road Medical** 波士顿科学宣布达成最终协议，以12亿美元收购专注于经颈动脉血管再通和支架系统的Silk Road Medical，以扩展其血管介入产品组合。
- **2024年第二季度：FDA批准美敦力的Onyx Frontier药物洗脱支架在美国市场上市** 美敦力获得FDA批准，其Onyx Frontier药物洗脱支架旨在治疗冠状动脉疾病，标志着该公司介入心脏病学业务的重要监管里程碑。
- **2024年第二季度：雅培获得Navitor经导管主动脉瓣植入系统的CE标志** 雅培宣布其Navitor TAVI系统获得CE标志批准，该系统包括一种新的动脉支架设计，用于欧洲的微创心脏瓣膜置换手术。
- **2024年第三季度：Biotronik在美国推出Pulsar-18 T3外周自膨胀支架** Biotronik宣布在美国商业推出其Pulsar-18 T3外周自膨胀支架，旨在治疗股腘动脉疾病，扩展其血管介入产品线。
- **2024年第三季度：微创医疗集团在中国获得Firehawk Liberty药物洗脱支架的NMPA批准** 微创医疗集团宣布其Firehawk Liberty药物洗脱支架已获得中国国家药品监督管理局（NMPA）的监管批准，用于治疗冠状动脉疾病。
- **2024年第三季度：Cordis宣布FDA批准SABERX药物涂层气球并推出新支架平台** Cordis获得FDA批准其SABERX药物涂层气球，并同时在美国推出新的外周动脉支架平台，增强其血管内产品供应。
- **2024年第四季度：波士顿科学在欧洲推出Synergy XD药物洗脱支架** 波士顿科学宣布在欧洲推出其Synergy XD药物洗脱支架，旨在改善冠状动脉疾病患者的可送达性和临床结果。
- **2024年第四季度：Terumo获得Ultimaster Tansei药物洗脱支架的FDA批准** Terumo宣布其Ultimaster Tansei药物洗脱支架获得FDA批准，使公司能够扩大在美国冠状介入市场的存在。
- **2025年第一季度：美敦力在日本推出Resolute Onyx 2.0 mm药物洗脱支架** 美敦力宣布在日本商业推出其Resolute Onyx 2.0 mm药物洗脱支架，针对小血管冠状动脉疾病的治疗。
- **2025年第一季度：生物传感器国际获得BioFreedom Ultra药物涂层支架的CE标志** 生物传感器国际宣布其BioFreedom Ultra药物涂层支架获得CE标志批准，允许在欧盟商业化，适用于冠状动脉疾病患者。
- **2025年第二季度：雅培将在爱尔兰开设新的血管设备制造设施** 雅培宣布计划在爱尔兰开设新的制造设施，专注于生产血管设备，包括动脉支架，以满足日益增长的全球需求。
- **2025年第二季度：波士顿科学任命新的介入心脏病学部门总裁** 波士顿科学宣布任命新的介入心脏病学部门总裁，负责监督公司的动脉支架及相关产品线。

当前的事务表明市场环境竞争激烈，主要参与者积极寻求占领市场份额，同时适应不断变化的医疗需求。整体市场估值呈上升趋势，受到心血管疾病发病率上升的推动，进一步刺激对先进支架技术的需求。这一财政趋势突显了动脉支架市场的健康增长前景，因为领先公司继续投资于研发，以增强可供医疗服务提供者的治疗选择。

## Report Scope

| 2024年市场规模 | 4.795（十亿美元） |
| --- | --- |
| 2025年市场规模 | 5.007（十亿美元） |
| 2035年市场规模 | 7.726（十亿美元） |
| 复合年增长率（CAGR） | 4.43%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 关键公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 关键市场机会 | 生物可降解支架技术的进步提高了动脉支架市场的患者结果。 |
| 关键市场动态 | 技术进步和监管变化正在重塑动脉支架市场的竞争动态。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，动脉支架市场的预计市场估值是多少？**
A: 动脉支架市场预计到2035年将达到77.26亿美元的估值。

**Q: 2024年动脉支架市场的市场估值是多少？**
A: 2024年，动脉支架市场的价值为47.95亿美元。

**Q: 在2025年至2035年的预测期内，动脉支架市场的预期CAGR是多少？**
A: 在2025年至2035年的预测期内，动脉支架市场的预期CAGR为4.43%。

**Q: 2024年哪种类型的支架段估值最高？**
A: 在2024年，药物洗脱支架部门的估值最高，达25亿美元。

**Q: 到2035年，裸金属支架的预计值是多少？**
A: 预计到2035年，裸金属支架的预计价值将达到24亿美元。

**Q: 到2035年，预计哪个应用领域将增长最多？**
A: 冠状动脉疾病应用领域预计将增长最多，到2035年达到38.63亿美元。

**Q: 到2035年，聚合物支架的预期市场规模是多少？**
A: 预计到2035年，聚合物支架的市场规模将达到19.3275亿美元。

**Q: 动脉支架市场的关键参与者是谁？**
A: 动脉支架市场的主要参与者包括美敦力、波士顿科学和雅培实验室等。

**Q: 到2035年，神经血管疾病应用领域的预计价值是多少？**
A: 预计到2035年，神经血管疾病应用领域的价值将达到15.54亿美元。

**Q: 到2035年，医院作为最终使用细分市场的预期市场规模是多少？**
A: 预计到2035年，医院作为最终使用细分市场的预期市场规模将达到38.63亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/arterial-stents-market-38501*